Research programme: cancer therapeutics - Regen BioPharma

Drug Profile

Research programme: cancer therapeutics - Regen BioPharma

Alternative Names: Checkpoint inhibitor pill - Regen BioPharma; dCellVax™; DiffronC; IDO-silenced cancer immunotherapeutic - Regen Biopharma; IDO-silenced dendritic cell vaccine - Regen Biopharma; NR2F6 inhibitors - Regen BioPharma; NR2F6 T cell immunotherapy; NR2F6-silenced cancer therapeutics - Regen BioPharma; RGBP-248; tCellVax; ucVAX; Universal donor cell therapy - Regen BioPharma

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Western Ontario
  • Developer Regen BioPharma; University of Lausanne; University of Western Ontario
  • Class Cancer vaccines; Dendritic cell vaccines; Gene therapies; Small interfering RNA; Small molecules
  • Mechanism of Action Dendritic cell modulators; Gene silencing; Gene transference; Immunostimulants; RNA interference; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Liver cancer
  • Research Colorectal cancer; Leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 15 Dec 2016 Regen BioPharma files a utility patent application with the USPTO for NR2F6 silenced CAR-T cells in USA
  • 14 Sep 2016 Regen BioPharma resubmits IND application with the US FDA for Breast cancer (Metastatic disease)
  • 13 Jul 2016 Regen BioPharma announces intention to resubmit an IND for dCellVax for Breast cancer treatment (Metastatic disease) to the US FDA in Q3 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top